Chinese Regulator Approves Essex Bio-Technology's Subsidiary's Eye Drops for Registration, Commercialization

MT Newswires Live08-14

Essex Bio-Technology's (HKG:1061) subsidiary Zhuhai Essex Bio-Pharmaceutical received the approval of the National Medical Products Administration for the registration and commercialization of preservative-free unit-dose Diquafosol Sodium Eye Drops in China, a Wednesday's filing with the Hong Kong Exchange said.

The approval does not include permissions for Taiwan and the special administrative regions of Hong Kong and Macao.

The eye drops are used in the treatment of dry eye syndromes like conjunctival epithelium injury and tear abnormalities. The drops contain 3% 3% (0.4ml:12mg) diquafosol sodium.

The company's shares were down nearly 2% on Wednesday's close.

Price (HKD): $2.39, Change: $-0.04, Percent Change: -1.65%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2459512777?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2459512777","market":"hk","top_or_hot":-1,"title":"Chinese Regulator Approves Essex Bio-Technology's Subsidiary's Eye Drops for Registration, Commercialization","media":"MT Newswires Live","content":"<html><body><p> Essex Bio-Technology's (HKG:1061) subsidiary Zhuhai Essex Bio-Pharmaceutical received the approval of the National Medical Products Administration for the registration and commercialization of preservative-free unit-dose Diquafosol Sodium Eye Drops in China, a Wednesday's filing with the Hong Kong Exchange said.</p><p>The approval does not include permissions for Taiwan and the special administrative regions of Hong Kong and Macao.</p><p>The eye drops are used in the treatment of dry eye syndromes like conjunctival epithelium injury and tear abnormalities. The drops contain 3% 3% (0.4ml:12mg) diquafosol sodium.</p><p>The company's shares were down nearly 2% on Wednesday's close.</p><p>Price (HKD): $2.39, Change: $-0.04, Percent Change: -1.65%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Regulator Approves Essex Bio-Technology's Subsidiary's Eye Drops for Registration, Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Regulator Approves Essex Bio-Technology's Subsidiary's Eye Drops for Registration, Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-14 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Essex Bio-Technology's (HKG:1061) subsidiary Zhuhai Essex Bio-Pharmaceutical received the approval of the National Medical Products Administration for the registration and commercialization of ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2459512777","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2459512777","pubTimestamp":1723636629,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Essex Bio-Technology's  subsidiary Zhuhai Essex Bio-Pharmaceutical received the approval of the National Medical Products Administration for the registration and commercialization of preservative-free unit-dose Diquafosol Sodium Eye Drops in China, a Wednesday's filing with the Hong Kong Exchange said.The approval does not include permissions for Taiwan and the special administrative regions of Hong Kong and Macao.The eye drops are used in the treatment of dry eye syndromes like conjunctival epithelium injury and tear abnormalities. The drops contain 3% 3%  diquafosol sodium.The company's shares were down nearly 2% on Wednesday's close.Price : $2.39, Change: $-0.04, Percent Change: -1.65%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4588":"碎股","BK4526":"热门中概股","HKD":"尚乘数科","BK4023":"应用软件"},"translate_title":"中国监管机构批准亿胜生物子公司滴眼液注册、商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"01061":0.9},"content_text":"Essex Bio-Technology's (HKG:1061) subsidiary Zhuhai Essex Bio-Pharmaceutical received the approval of the National Medical Products Administration for the registration and commercialization of preservative-free unit-dose Diquafosol Sodium Eye Drops in China, a Wednesday's filing with the Hong Kong Exchange said.The approval does not include permissions for Taiwan and the special administrative regions of Hong Kong and Macao.The eye drops are used in the treatment of dry eye syndromes like conjunctival epithelium injury and tear abnormalities. The drops contain 3% 3% (0.4ml:12mg) diquafosol sodium.The company's shares were down nearly 2% on Wednesday's close.Price (HKD): $2.39, Change: $-0.04, Percent Change: -1.65%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2459512777"}